SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.23
+5.22%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.07
From 52W high−67.61%
Volume1.51M
Market cap$420.66M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataOct 19, 2026
Open
$4.07
From 52W high
−67.61%
Volume
1.51M
Market cap
$420.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
46.4
MomentumView details →
1D Return
+5.22%
YTD Return
−63.21%
SummaryUpdated Jun 1, 2026
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a commercial-stage biotechnology company founded in 2015 and headquartered in San Diego, California. The company went public in December 2020 and has developed a breakthrough needle-free epinephrine treatment for severe allergic reactions. After years of clinical development and regulatory approval processes, ARS successfully launched its flagship product <b>neffy</b> in the United States in September 2024, marking a significant milestone as the first and only needle-free epinephrine treatment approved by the FDA. The company has also secured regulatory approvals in Europe and is expanding globally through strategic partnerships.
Similar companies
Latest newsMore news →
The DJS Law Group reminded investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.28d agoKaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. on behalf of investors who acquired ARS securities between March 9, 2026 and June 24, 2026, with a lead plaintiff deadline of October 5, 2026.31d agoA securities class action lawsuit was filed against ARS Pharmaceuticals, Inc. in the U.S. District Court for the Southern District of California on behalf of investors who purchased more than $100,000 of its shares between March 9, 2026 and June 24, 2026, with a deadline of October 5, 2026.34d ago